Abrogation of Chk1-mediated S/G2 checkpoint by UCN-01 enhances ara-C-induced cytotoxicity in human colon cancer cells

Acta Pharmacologica Sinica

Volumn 25, Issue 6, 2004, Pages 756-762

  Shao, Rong Guang ^a   Cao, Chun Xia ^a   Pommier, Yves ^b  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

7 Hydroxystaurosporine; Cell cycle; Chk1 protein kinase; DNA repair

Indexed keywords

7 HYDROXYSTAUROSPORINE; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 25C; CHECKPOINT KINASE 1; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE 2; CYTARABINE; PHOSPHOTRANSFERASE; PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CLONOGENIC ASSAY; COLON CANCER; COLONY FORMATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CDC2-CDC28 KINASES; CDC25 PHOSPHATASE; CELL CYCLE PROTEINS; CYCLIN A; CYCLIN B; CYCLIN-DEPENDENT KINASE 2; CYTARABINE; DNA, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; G2 PHASE; HT29 CELLS; HUMANS; PROTEIN KINASES; S PHASE; STAUROSPORINE;

EID: 2942599254     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421-9.
2. Shackelford RE, Kaufmann, WK, Paules RS. Cell cycle control, checkpoint mechanisms, and genotoxic stress. Environ Health Perspect 1999; 107: 5-24.
3. Yu Q, La Rose J, Zhang H, Takemura H, Kohn KW, Pommier Y. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res 2002; 62: 5743-8.
4. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996; 88: 956-65.
5. Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997; 57: 4029-35.
6. Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2 checkpoint inhibitor. Clin Cancer Res 1996; 2: 791-7.
7. Bunch RT, Eastman A. 7-hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S phase arrest in Chinese hamster ovary cells. Cell Growth Differ 1997; 8: 779-88.
8. Shao RG, Cao CX, Zhang H, Kohn KW, Wold MS, Pommier Y. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA: DNA-PK complexes. EMBO J 1999; 18: 1397-406.
9. Akinaga S, Gomi K, Morimoto M, Tomaoki T, Okabe M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 1991; 51: 4888-92.
10. Seynaeve CM, Kazanietz MG, Blumberg PM, Sausville EA, Worland PJ. Differential inhibition of protein kinase C isozymes by, UCN-01, a staurosporine analogue. Mol Pharmacol 1994; 45: 1207-14.
11. Akinaga S, Nomura K, Gomi K, Okabe M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01 a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol 1993; 32: 183-9.
12. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 1997; 277: 1497-501.
13. Rodrigues NR, Rowan A, Smith MEF, Kerr IB, Bodmer WF, Gannon JV, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990; 87: 7555-9.
14. Akiyama T, Yoshida T, Tsujita T, Shimizu M, Mizukami T, Okabe M. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 19976; 57: 1495-501.
15. O'Connor PM. Mammalian G1 and G2 phase checkpoints. Cancer Surv 1997; 29: 151-82.
16. Yu L, Orlandi L, Wang P, Orr MS, Senderowicz AM, Sausville EA, et al. UCN0-01 abrogates G2 arrest though a Cdc2-dependent pathway that is associated with inactivation of the WeelHu kinase and activation of the cdc25C phosphatase. J Biol Chem 1998; 273: 33455-64.
17. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worma H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997; 277: 1501-5.
18. Lopez-Girona A, Fumari B, Mondesert O, Russell P. Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature 1999; 397: 172-5.
19. Duncker BP, Pasero P, Braguglia D, Heun P, Weinreich M, Gasser SM. Cyclin B-cdk1 kinase stimulates ORC- and Cdc6-independent steps of semiconservative plasmid replication in yeast nuclear extracts. Mol Cell Biol 1999; 19: 1226-41.
20. Gabrielli BG, Clark JM, McCormack AK, Ellem KA. Hyperphosphorylation of the N-terminal domain of Cdc25 regulates activity toward cyclin B1/Cdc2 but not cyclin A/Cdk2. J Biol Chem 1997; 272: 28607-14.
21. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000; 275: 5600-5.
22. Chen Z, Xiao Z, Chen J, Ng SC, Sowin T, Sham H, et al. Human chk1 expression is dispensable for somatic cell death and critical for sustaining G(2) DNA damage checkpoint. Mol Cancer Ther 2003; 2: 543-8.
23. Wang H, Wang X, Zhou XY, Chen DJ, Li GC, Iliakis G, et al. An ATM-independent S-phase checkpoint response involves CHK1 pathway. Cancer Res 2002; 62: 1598-603.
24. Wang JL, Wang X, Wang H, Iliakis G, Wang Y. CHK1-regulated S-phase checkpoint response reduces camptothecin cytotoxicity. Cell Cycle 2002; 1: 267-72.